Actavis today confirmed that the United States Court of Appeals for the Federal Circuit has granted AstraZeneca’s request for an injunction pending appeal preventing Actavis from further distribution of its generic version of Pulmicort.
Under the ruling, Actavis’ sales of generic Pulmicort have been enjoined pending the resolution of AstraZeneca’s appeal before the Court. The Court has set an expedited briefing schedule for the appeal, with expedited briefing to be concluded within 33 days. The injunction does not address product shipped prior to its issuance.
Full Content: The AM Law Litigation Daily
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Japan’s Prime Minister Criticizes US Block on Nippon Steel-US Steel Deal
Feb 17, 2025 by
CPI
UAE Cabinet Announces New Merger Control Filing Thresholds Effective March 2025
Feb 17, 2025 by
CPI
UK Regulator Warns Topps Tiles Acquisition Could Hurt Competition
Feb 17, 2025 by
CPI
FTC Chair Andrew Ferguson Backs Trump’s Authority to Remove Commissioners
Feb 17, 2025 by
CPI
South Korea Suspends Downloads of Chinese AI App DeepSeek Over Data Privacy Concerns
Feb 17, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – International Criminal Enforcement
Jan 23, 2025 by
CPI
The Antitrust Division’s Recent Work to Combat International Cartels
Jan 23, 2025 by
Emma Burnham & Benjamin Christenson
Information Sharing: The New Frontier of U.S. Antitrust Enforcement
Jan 23, 2025 by
Brian P. Quinn, Casey Kovarik & Michael Tubach
The Key Role of Guidelines on Exchanges of Information Among Competitors and the Divergent Transatlantic Paths
Jan 23, 2025 by
Rosa Abrantes-Metz & Albert Metz
Leniency, Whistleblowers, and Compliance
Jan 23, 2025 by
Richard Powers, Tara O’Malley & Cory Gordon